Important Notice for Shareholders of Cardlytics, Inc.
New York, NY, March 20, 2025
The Gross Law Firm, a leading national shareholder rights law firm, issues this notice to shareholders of Cardlytics, Inc. (CDLX). If you purchased shares of CDLX during the class period of February 1, 2022, to November 1, 2024, you may have been affected by potential securities fraud and may be eligible to participate in a securities class action against the company.
Class Action Details
The Gross Law Firm, in collaboration with co-lead counsel, is investigating allegations that Cardlytics, Inc. and certain of its executives and directors may have violated federal securities laws. Specifically, the complaint, filed on March 13, 2025, in the United States District Court for the Northern District of Georgia, alleges that Cardlytics made materially false and misleading statements regarding the company’s business, operational, and financial metrics.
The complaint alleges that the defendants failed to disclose material information concerning the company’s business, including, but not limited to, its financial condition and prospects. As a result of these alleged false statements, CDLX stock traded at artificially inflated prices during the class period.
Shareholder Rights and Potential Lead Plaintiff Appointment
If you purchased CDLX shares during the class period and have suffered a loss, you may be eligible to be a lead plaintiff in the class action. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. The lead plaintiff can select a law firm of their choice to represent the class. An experienced securities litigation firm, such as The Gross Law Firm, is typically appointed as lead counsel in these types of actions.
Impact on Individual Shareholders
If the allegations against Cardlytics are proven true, individual shareholders who purchased CDLX shares during the class period may be entitled to recover their losses. The recovery process is designed to make shareholders whole by returning them to the position they would have been in if they had not bought the shares. This can include damages, as well as any offsetting gains realized from the sale of the shares.
Impact on the World
The potential fallout from this securities class action could extend beyond the affected shareholders. The allegations, if proven true, could damage Cardlytics’ reputation and potentially impact investor confidence in the technology sector. Moreover, the litigation could result in increased scrutiny and regulation of the financial reporting practices of publicly traded companies.
Next Steps for Affected Shareholders
If you purchased CDLX shares during the class period and believe you have been harmed as a result of the alleged securities fraud, you are encouraged to contact The Gross Law Firm as soon as possible. The firm’s experienced securities litigation team will evaluate your potential claim at no cost to you and advise you on how to protect your rights.
- Email: [email protected]
- Phone: +1-212-504-5453
- Contact Us
Do not delay: The class action has strict deadlines. If you miss the deadlines, your ability to participate and recover your losses may be permanently barred.
Conclusion
The securities class action against Cardlytics, Inc. could have significant implications for affected shareholders and the broader financial markets. If you purchased CDLX shares during the class period, it is essential that you take action now to protect your rights. Contact The Gross Law Firm today to discuss your potential claim and learn more about the litigation process.
